Apomorphine in the treatment of Parkinson's disease

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 12, 2007, Pages 1941-1950

  Menon, Rukmini ^a   Stacy, Mark ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apomorphine; Motor fluctuations; Off symptoms; Wearing off phenomenon

Indexed keywords

ANTIEMETIC AGENT; ANTIPARKINSON AGENT; APOMORPHINE; CORTICOSTEROID; CREATININE; DOMPERIDONE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; METOCLOPRAMIDE; ONDANSETRON; PLACEBO; TRIMETHOBENZAMIDE; UREA;

ANGINA PECTORIS; ANXIETY; ARTHRALGIA; BACKACHE; BRAIN DEPTH STIMULATION; BURNING SENSATION; CLINICAL TRIAL; CONFUSION; CONSCIOUSNESS DISORDER; CONTINUOUS INFUSION; COOMBS POSITIVE HEMOLYTIC ANEMIA; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPNEA; EVIDENCE BASED MEDICINE; FAINTNESS; FLUSHING; GRANULOMA; HALLUCINATION; HEMOLYTIC ANEMIA; HUMAN; HYPERSEXUALITY; HYPOTENSION; INJECTION SITE NODULE; INJECTION SITE REACTION; INSOMNIA; LIMB PAIN; LIMB SWELLING; MASSAGE; MENTAL DISEASE; MOTOR DYSFUNCTION; NAUSEA; NAUSEA AND VOMITING; NOSE CONGESTION; NOSE DISEASE; NOSE IRRITATION; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL EDEMA; PNEUMONIA; PRIAPISM; QT INTERVAL; QT PROLONGATION; REVIEW; RHINORRHEA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STOMATITIS; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS NODULE; TASTE DISORDER; THORAX PAIN; THROMBOSIS; TREATMENT DURATION; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINARY TRACT INFECTION; VOMITING; YAWNING;

ANTIPARKINSON AGENTS; APOMORPHINE; DRUG ADMINISTRATION ROUTES; DYSKINESIAS; HUMANS; PARKINSON DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

EID: 34548282615     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.12.1941     Document Type: Review

References (76)

1. PAHWA R, LYONS KE: Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review. Neurol. Clin. (2004) 22(Suppl. 3):S35-S52.
2. SWOPE DM: Rapid treatment of "wearing off" in Parkinson's disease. Neurology (2004) 62(Suppl. 4):S27-S31.
3. MATTHEISSEN A, WRIGHT CR: Research into the chemical constitution of the opium bases. Part 1: on the action of hydrochloric acid on morphia. Proc. R. Soc. Lond. B. Biol. Sci. (1869) 17:455-460.
4. ZURICH FM: Apomorphine. The formation of apomorphine on heating and preserving morphine solutions. Z. Physiol. Chem. (1913) 84:363-378.
5. WEIL E: De l'apomorphine dans certain troubles nerveux. Lyon. Med. (1884) 48:411-419.
6. SCHWAB RS, AMADOR LV, LETTVIN JY: Apomorphine in Parkinson's disease. Trans. Am. Neural Assoc. (1951) 56:251-253.
7. COTZIAS GC, PAPAVASILIOU PS, FEHLING C et al.: Similarities between neurologic effects of L-Dopa and of apomorphine: N. Engl. J. Med. (1970) 282:31-33.
8. ERNST AM: Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia (1967) 10:316-323.
9. ANDEN NE, RUBENSON A, FUXE K, HOKFELT T: Evidence of dopamine receptor stimulation by apomorphine. J. Pharm. Pharmacol. (1967) 19:627-629.
10. CASTAIGNE P, LAPLANE D, DORDAIN G: Clinical experimentation with apomorphine in Parkinson's disease. Res. Commun. Chem. Pathol. Pharmacol. (1971) 2(2):154-158.
11. COTZIAS GC, PAPAVASILIOU PS, TOLOSA ES, MENDEZ JS, BELL-MIDURA M: Treatment of Parkinson's disease with apomorphines: possible role of growth hormones. N. Engl. J. Med. (1976) 295:567-572.
12. KLEIN RL, MILITELLO TE, BALLINGER CM: Antiemetic effect of metoclopramide. Evaluation in humans. Anesth. Analg. (1968) 47:259-264.
13. GYLDING-SABROE JP, HATTEL T: Metoclopramide. A new quick acting antiemetic. Nord. Med. (1969) 81:141-142.
14. CORSINI GU, GESSA GL, DEL ZOMPO M, MANGONI A: Therapeutic efficacy of apomorphine combined with extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet (1979) 1:954-956.
15. STIBE CM, KEMPSTER PA, LEES AJ, STERN GM: Subcutaneous apomorphine in Parkinsonian on-off oscillations. Lancet (1988) 1:403-406.
16. OSTERGAARD L, WERDELIN L, ODIN P: Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind placebo controlled study. J. Neurol. Neurosurg. Psychiatry (1995) 58:681-687.
17. MERELLO M, PIKIELNY R, CAMMAROTA A, LEIGUARDA R: Comparison of subcutaneons apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double blind placebo controlled study. Clin. Neuropharmacol. (1997) 20:165-167.
18. DEWEY RB Jr, HUTTON JT, LEWITT PA, FACTOR SA: A randomized, double-blinded, placebo-controlled trial of subcutaneous injected apomorphine for parkinsonian off-state events. Arch. Neurol. (2001) 58(9):1385-1392.
19. HUTCHINSON WD, LEVY R, DOSTROVSKY JO, LOZANO AM, LANG AE: Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann. Neurol. (1997) 42(5):767-775.
20. NEUMEYER JL, BALDESSARINI RJ, ARANA GW, CAMPBELL A: Aporphines as dopamine receptor agonists and antagonists at central dopamine receptors. New Methods Drug Res. (1985) 1:153-166.
21. FACTOR SA: Dopamine agonists. Med. Clin. North Am. (1999) 83(2):415-443.
22. DUBY SE, COTZIASGC, PAPAVASILIOU PS, LAWRENCE WH: Injected apomorphine and orally administered levodopa in Parkinsonism. Arch. Neurol. (1972) 27(6):474-480.
23. SHERRY JH GP, VAN LUNEN B, BOTTINI PB: Coutinued efficacy and safety of subcutaneous injections of apomorphine in the treatment of "off" episodes in patients with Parkinson's disease. Neurology (2003) 60(Suppl. 1):A81.
24. NEWMAN-TACREDI A, CUSSAC et al.: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of Dopamine D2-like receptors and α1/α2-adrenoceptor. J. Pharmacol. Exp. Ther. (2002) 303:805-814.
25. MILLAN MJ, MAIOFUSS L, CUSSAC D et al.: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. (2002) 303:791-804.
26. NEWMAN-TACREDI A, CUSSAC et al.: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1,and 5-HT2 receptor subtypes. J. Pharmacol. Exp. Ther. (2002) 303:815-822.
27. ZHANG AO, ZHANG Y, BRANFMAN AR, BALDESSARINI RJ, NEUMEYER JL: Advances in the development of doapminergic aporphinoids. J. Med. Chem. (2007) 50(2):171-181.
28. 2 and 6-hydroxydopamine. Mov. Disord. (1998) 13(2):242-248.
29. GRUNBLATT E, MANDEL S, BERKUZKI T, YOUDIM MBH: Apomorphine protects against MPTP-induced neuroroxicity in mice. Mov. Disord. (1999) 14(4):612-618.
30. KUNO S, OHTA M, OTHA K, MIZUTA I: Expression of neurotrophic factors in cultured mouse astroglial cells by apomorphine. Mov. Dis. (2000) 15(Suppl. 3):23.
31. GAUCHER ST, WOODWARD WR, BOUCHER B et al.: Peripheral pharmacokinetics of apomorphine in humans. Ann. Neurol. (1989) 26:232-238.
32. NICOLLE E, POLLAK P, SERRE-DEBEAUVAIS F et al.: Pharmacokinetics of apomorphine in Parkinsonian patients. Fundam. Clin. Pharmacol. (1993) 7:245-252.
33. HARDER S, BAAS H, DEMISCH L, SIMON E: Dose response and concentration response relationship of patients with Parkinson's disease and end-of-dose akinesia. Int. J. Clin. Pharmacol. Ther. (1998) 36:355-362.
34. HOFSTEE DJ, NEEF CO VAN LAAR, JANSEN EN: Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses. Clin. Neuropharmacol. (1994) 17:45-52.
35. NEEF C, VAN LAAR T: Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin. Pharmacokinet. (1999) 37:257-271.
36. KAUL PN, BROCHMAN-HANSSEN E, WAY EL: Biological disposition of apomorphine. Urinary excretion and organ distribution of apomorphine. J. Pharma. Sci. (1961) 50:244-247.
37. VAN DER GEEST R, KRUGER P, GUBBENS-STIBBE JM et al.: Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulphate conjugates in plasma and urine of patients with Parkinson's disease. J. Chromatogr. B (1997) 702:131-141.
38. VAN DER GEEST R, KRUGER PP et al.: Pharmacokinetics, enantiomer interconversion and metabolism of the R-apomorphine in patients with idiopathic Parkinson's disease. Clin. Neuropharmacol. (1998) 21:159-168.
39. VERHAGEN ML, LOCATELI ER, BRAVI D et al.: Apomorphine responses in Parkinson's disease and pathogenesis of motor complications. Neurology (1997) 48:369-372.
40. STACY M: Apomorphine North American clinical experience. Neurology (2004) 62(Suppl.):S18-S21.
41. PFEIFER RF, GUTMAN L, HULL KL et al.: Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat. Disord. (2007) 13(2):93-100.
42. TROSCH R: Decrease in UPDRS motor scores following intermittent subcutaneous apomorphine for 6 months in patients with advanced Parkinson's disease. Mov. Disord. (2004) 19(Suppl. 9):S217.
43. HARDIE RJ, LEES AJ, STERN GM: On-off fluctnations in Parkinson's disease. A clinical and neuropharmacological study. Brain (1984) 107(2):487-506.
44. VAN LAAR T, JANSEN EN, ESSINK AW, NEEF C: A double-blind study of the efficacy of apomorphine and its assessment in "off" periods in Parkinson's disease. Clin. Neurol. N'eurosurg. (1993) 95(3):231-235.
45. HUGHES AJ, BISHOP S, KLEEDORFER B et al.: Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov. Disord. (1993) 8(2):165-170.
46. DELEU D, NORTHWAY MG, HANSSENS Y: Clinical pharmacokinetics and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin. Pharmacominet. (2002) 41(4):261-309.
47. DELEU D, HANSSENS Y, NORTHWAY MG: Subcutaneous apomorphine: an evidence based review of its use in Parkinson's disease. Drugs Aging (2004) 21:687-709.
48. BOWRON A: Practical considerations in the use of apomorphine injectable. Neurology (2004) 62(Suppl. 4):S32-S36.
49. LEES AJ, RICHARDSON C, TURNER K: Treatment of Parkinson's disease with apomorphine. Shared guidelines, 3rd Edition. UCL Hospitals, NHS trust (1998).
50. PIETZ K, HAGELL P, ODIN P: Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J. Neurol Neurosurg. Psychiatry(1998) 65(5):709-716.
51. HAGELL P, ODIN P: Apomorphine in the treatment of Parkinson's disease. J. Neurosci. Nursing (2001) 33(1):21-37.
52. MANSON AJ, HANAGASI H, TURNER K et al.: Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observation. Brain (2001) 124:331-340.
53. ESTEBAN MUNOZ J, MARTI MJ, MARIN C, TOLOSA E: Long term treatment with intermittent intranasal or subcutaneous apomorphine in patients with levodopa-related motor fluctuations. Clin. Neuropharmacol. (1997) 20:245-252.
54. KLEEDORFER B, TURJANSKI N, RYAN R et al.: Intranasal apomorphine in Parkinson's disease. Neurology (1991) 41:761-762.
55. DEWEY RB Jr, MARAGANORE DM, AHLSKOG JE, MATSUMOTO JY: Intranasal apomorphine rescue therapy for Parkinsonian "off" periods. Clin. Neuropharmacol. (1996) 19:193-201.
56. DEWEY RB Jr, MARAGANORE DM, AHLSKOG JE, MATSUMOTO JY: A double-blind placebo-eontrolled study of intranasal apomorphine as a rescue agent for off-states in Parkinson'a disease. Mov. Disord. (1998) 13(5):782-787.
57. MONTASTRUC JL, RASCOL O, SENARD JM et al.: Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin. Neuropharmacol. (1991) 14:432-437.
58. DURIF F, DEFFOND D, DORDAIN G et al.: Apomorphine and diphasic dyskinesia. Clin. Neuropharmacol. (1994) 17:99-102.
59. ONDO W, HUNTER C, ALMAGUER M, JANKOVIC J: A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov. Disord. (1999) 14:664-668.
60. HUGHES AJ, WEBSTER R, BONINGDON M, LEES AJ, STERN GM: Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. Clin. Neuropharmacol. (1991) 14:556-561.
61. VAN LAAR T, JANSEN EN, NEEF C, DANHOF M, ROOS RA: Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov. Discord. (1995) 10:433-439.
62. HUGHES AJ, BISHOP S, LEES AJ, STERN GM, WEBSTER R, ROVINGTON M: Rectal apomorphine in Parkinson's disease. Lancet (1991) 337:118.
63. DODEL RC, BERGER K, OERTEL WH: Health related quality of life and healthcare utilization in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics (2001) 19:1013-1038.
64. SCHRAG A, QUINN N: Dyskinesias and motor fluctuations in Parkinson's disease: a community based study. Brain (2000) 123:2297-2305.
65. STACY M, BOWRON A, GUTTMAN M et al.: Identification of motor and non-motor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov. Disord. (2005) 20:726-733.
66. CARTER JH, STEWART BJ, ARCHBOLD PG et al.: Living with a person who had Paskinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group. Mov. Dis. (1998) 113:20-28.
67. DE GASPARI D, SIRI C, LANDI A et al.: Clinical and neurophysiological follow up at 12 months on patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J. Neurol. Neurosurg. Psychiatry (2006) 77:450-453.
68. KEMPSTER PA, FRANKEL JP, STERN GM, LEES AJ: Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J. Neural Neurosurg. Psychiatry (1990) 53:1004-1007.
69. POLLAK P, CHAMPAY AS, HOMMEL M et al.: Subcutaneous apomorphine in Parkinson's disease. J. Neural Neurosurg. Psychiatry (1989) 52:544.
70. POEWE W, KLEEDORFER B, GERSTENBRAND F, ORTEL W: Subcutaneous apomorphine in Parkinson's disease. Lancet (1988) 1:943.
71. POEWE W, KLEEDORFER B, WAGNER M et al.: Side effects of subcutaneous apomorphine in Parkinson's disease. Lancet (1989) 1:1084-1085.
72. FRANKEL JP, LEES AJ, KEMPSTER PA, STERN GM: Subcutaneous apomorphine in the treatment of Parkinson's disease. J. Neural Neurosurg. Psychiatry (1990) 53:96-101.
73. HUGHES AJ, LEES AJ, STERN GM: The motor response to sequential apomorphine in parkinsonian fluctuations. J. Neural Neurosurg. Psychiatry 0991) 54:358-360.
74. HUGHES AJ, BISHOP S, STERN GM, LEES AJ: The motor response to repeated apomorphine administration in Parkinson's disease. Clin. Neuropharmacol. (1991) 14:209-213.
75. DEFFOND D, DURIF F, TOURNILHAC M: Apomorphine in the treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes. J. Neurol. Neurosurg. Psychiatry (1993) 56:101-103.
76. GERVASON CL, POLLAK PR, LIMOUSIN P, PERRET JE: Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinso's disease. Clin. Neuropharmacol. (1993) 16:113-119.